Drug intelligence / Profile preview

SCH 900800

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

SCH 900800 is an investigational drug that has been studied in clinical trials for Parkinson's disease, specifically to assess its pharmacokinetics when administered as oral tablets in L-DOPA-treated subjects. The precise mechanism of action, chemical structure, and broader pharmacological profile are not detailed in the available sources. The drug appears to be under development for neurological disorders such as Parkinson's disease. **Developer:** Merck

Beyond the preview

Go deeper on SCH 900800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCH 900800.

Explore the full profile